Search

Search Constraints

You searched for: Author/Creator Lowry, Simon

Search Results

1. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. (3rd October 2021)

2. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. (17th February 2022)

6. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. (16th November 2020)